Japan Cancer Immunotherapy Market Size & Outlook, 2026-2033

The cancer immunotherapy market in Japan is expected to reach a projected revenue of US$ 11,922.6 million by 2033. A compound annual growth rate of 10.5% is expected of Japan cancer immunotherapy market from 2026 to 2033.
Revenue, 2025 (US$M)
$5,370.6
Forecast, 2033 (US$M)
$11,922.6
CAGR, 2026 - 2033
10.5%
Report Coverage
Japan

To keep accessing Horizon, please sign in or register for a free account

  • Access to global market statistics
  • Access to company profiles
  • Free use-cases & research insights

No credit card required*

Japan cancer immunotherapy market, 2021-2033 (US$M)

To keep accessing Horizon, please sign in or register for a free account

  • Access to global market statistics
  • Access to company profiles
  • Free use-cases & research insights

No credit card required*

Japan cancer immunotherapy market highlights

  • The Japan cancer immunotherapy market generated a revenue of USD 5,370.6 million in 2025 and is expected to reach USD 11,922.6 million by 2033.
  • The Japan market is expected to grow at a CAGR of 10.5% from 2026 to 2033.
  • In terms of segment, monoclonal antibodies was the largest revenue generating product in 2025.
  • Oncolytic Viral Therapies and Cancer Vaccines is the most lucrative product segment registering the fastest growth during the forecast period.


Cancer immunotherapy market data book summary

Market revenue in 2025USD 5,370.6 million
Market revenue in 2033USD 11,922.6 million
Growth rate10.5% (CAGR from 2026 to 2033)
Largest segmentMonoclonal antibodies
Fastest growing segmentOncolytic Viral Therapies and Cancer Vaccines
Historical data2021 - 2024
Base year2025
Forecast period2026 - 2033
Quantitative unitsRevenue in USD million
Market segmentationMonoclonal Antibodies, Check Point Inhibitors, Oncolytic Viral Therapies and Cancer Vaccines
Key market players worldwidePfizer Inc, AstraZeneca PLC, Merck & Co Inc, Roche Holding AG, Bristol-Myers Squibb Co, Novartis AG ADR, Eli Lilly and Co, Johnson & Johnson, Immunocore Holdings PLC ADR


Other key industry trends

  • In terms of revenue, Japan accounted for 3.5% of the global cancer immunotherapy market in 2025.
  • Country-wise, U.S. is expected to lead the global market in terms of revenue in 2033.
  • In Asia Pacific, China cancer immunotherapy market is projected to lead the regional market in terms of revenue in 2033.
  • India is the fastest growing regional market in Asia Pacific and is projected to reach USD 6,761.3 million by 2033.

Monoclonal antibodies was the largest segment with a revenue share of 69.66% in 2025. Horizon Databook has segmented the Japan cancer immunotherapy market based on monoclonal antibodies, check point inhibitors, oncolytic viral therapies and cancer vaccines covering the revenue growth of each sub-segment from 2021 to 2033.


Rapidly aging population in Japan is one of the factors widening the cancer patient pool in the country. The treatment paradigm for cancer in Japan is steadily shifting toward immunotherapeutic options post the development of Opdivo by immunologist Tasuku Honjo, which won him the Nobel Prize in Physiology or Medicine in 2018.

In May 2019, Kyoto University collaborated with Honjo & his team to develop the first cancer immunotherapy research center in Japan. Currently, the three major approaches used in cancer immunotherapy in Japan are adoptive cell transfer therapy, immune checkpoint blockade, and active vaccination.

Technological advancements in the field of medical science is fuelling the growth of cancer immunotherapy market in Japan. For instance, the advent of NGS technology has enabled genetic background of human cancers and identifications of potent neoantigens.

No credit card required*

Horizon in a snapshot

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more

Cancer Immunotherapy Market Companies

Name Profile # Employees HQ Website
Immunocore Holdings PLC ADR View profile 497 92 Park Drive, Milton Park, Abingdon, Oxfordshire, United Kingdom, OX14 4RY https://www.immunocore.com
AstraZeneca PLC View profile 89900 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, United Kingdom, CB2 0AA https://www.astrazeneca.com
Eli Lilly and Co View profile 43000 Lilly Corporate Center, Indianapolis, IN, United States, 46285 https://www.lilly.com
Bristol-Myers Squibb Co View profile 34100 Route 206 and Province Line Road, Princeton, New Jersey, NJ, United States, 08543 https://www.bms.com
Merck & Co Inc View profile 72000 126 East Lincoln Avenue, Rahway, NJ, United States, 07065 https://www.merck.com
Roche Holding AG View profile 103605 Grenzacherstrasse 124, Basel, Switzerland, 4070 https://www.roche.com
Pfizer Inc View profile 88000 66 Hudson Boulevard East, New York, NY, United States, 10001-2192 https://www.pfizer.com
Novartis AG ADR View profile 76057 Lichtstrasse 35, Basel, Switzerland, 4056 https://www.novartis.com
Johnson & Johnson View profile 134400 One Johnson and Johnson Plaza, New Brunswick, NJ, United States, 08933 https://www.jnj.com

Japan cancer immunotherapy market size, by product, 2021-2033 (US$M)

Japan Cancer Immunotherapy Market Outlook Share, 2025 & 2033 (US$M)

Japan cancer immunotherapy market size, by product, 2021-2033 (US$M)

Sign up - it's easy, and free!

Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our free plan indefinitely.

Explore all plans

Included in Horizon account

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more
Chat with us
Research Assistance
Online